BioCryst Pharmaceuticals Inc (BCRX) Noticias

BCRX under $10

BCRX under $8

BCRX new 52 week low

BCRX new 52 lo

BCRX new 52 week lo

BCRX under $10

BCRX 10Q 2/26

It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper

when will it turn around?

when will it turn around?

Huge buys in AH

Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?

6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.

Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.

I guess it was perfect timing in a way...

I reduced my position here to buy more AUPH (facepalm)

13.90s pullback yesss

Overbought pullback in progress TA saves money

You were saying? LMFAO!!!!!!!!

BCRX just on CNBC for large call volume action

Burnt to a crisp rsi enjoy

Lmfao the rsi is 100 pullback in progress

Understatement

This company is a juggernaut!

Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA

Great buying opportunity.
Shouldn't be this low.

What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.

Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more

Might buy some options here

Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.

I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.

First sign of life….someone realizes that this a buy

Yeah been 18 months now and holding for me . I thin pnh results soon will help us

I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.

Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials

The sharp increase in revenue is what got my attention!

"Facepalm" I jinxed you guys.

Hi Cosa, welcome…

Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.

Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.

Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside

Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year

Oh okay, so I can buy some for long term? Thanks in advance.

It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!

How?

Embarrassment of riches!

I think it is a public show of the poison pill clause. There may have been a potential buyer who wanted to play hard ball but got cock-blocked by Jon "Biochad" Stonehouse.

Totally agree. No one saw secondary offering coming after upbeat ER. No one ever saw another offer being pulled. Company owes us a true explanation re timing and intent

Some crazy shit Stoney pulled off today!!!